The purpose of this research is to evaluate the efficacy of dosing iloperidone long-acting injection (LAI) compared to placebo in preventing the exacerbation of symptoms in patients with schizophrenia.
Protocol Amendment History
2 amendments
This ClinicalTrials.gov record has been amended 2 times since 2025-04-29; most recent amendment 2026-01-09.
Status change: Not Yet Recruiting → Recruiting2025-09-05